linjc16/ctgov huggingface dataset:
Balloon Catheters in Cases of Abnormal Placentation

Study Overview
=================
Brief Summary
-----------------
Placenta accreta is a relatively rare event, in which the placenta is abnormally implanted into the uterine myometrium. The most significant complication is intense bleeding, mainly during labor. The most important risk factors are previous cesarean delivery, placenta previa, and advanced maternal age. Cesarean hysterectomy is the recommended management. During the recent years, inserting intravascular balloon catheter for occlusion and/or arterial embolization, was introduced as an adjuvant therapy in order to minimize blood loss during cesarean hysterectomy or in conduct with conservative management with the intent of avoiding hysterectomy in selective cases. Contradicting reports exist regarding the effectiveness and safety of the catheters in cases of placenta accreta. The objective of this study is to estimate the efficacy of the balloon catheters among women diagnosed with a placenta accreta.

Official Title
-----------------
Balloon Catheter for Occlusion of the Pelvic Vasculature as an Adjuvant Therapy in Cases of Placenta Accreta

Conditions
-----------------
Post Partum Bleeding

Intervention / Treatment
-----------------
* Procedure: internal iliac catheterization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women age 18-45 antepartum diagnosis of placenta accreta Exclusion Criteria: - women who refuse to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: internal iliac catheterization<br>Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery | Procedure: internal iliac catheterization<br>* Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery<br>* Other names: internal iliac artery catheterization;|
| No Intervention: No intervention<br>no intervention prior to cesarean | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of blood products transfused |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need for hysterectomy |  | 5 years | 
| catheter's side effects |  | 5 years | 
| Length of hospitalization |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Placenta accreta, Internal iliac artery catheterization, Post partum bleeding
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)

Study Overview
=================
Brief Summary
-----------------
The aim of the study proposed in Dijon is above all to focus on the possible relationship between age-related ocular pathologies (AMD and glaucoma) and et les degenerative neurological and cardiac pathologies. The principal objective is to seek in subjects who have undergone cerebral MRI and echocardiography, associations between the thickness of postganglionic fibers measured by Optical Coherence Tomography at the 7th year (n=1500) and signs of cerebral impairment (psycho-cognitive tests, circulation time, MRI signs). This association will be studied after taking into account the principal environmental (particularly dietary) and genetic risk factors.

Official Title
-----------------
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort): Seek Correlations Between Signs of Neurological and Vascular Degeneration and Signs of Ocular Aging

Conditions
-----------------
AMD, Glaucoma

Intervention / Treatment
-----------------
* Procedure: Optical Coherence Tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons who have given their written consent Persons who are taking part in the Dijon 3C study Exclusion Criteria: Persons who are not registered with social security agency Persons who are unable to sit upright during a consultation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 3C cohort<br> | Procedure: Optical Coherence Tomography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure the mean thickness of postganglionic fibers | Measure the thickness of postganglionic fibers by Optical Coherence Tomography in the 4 quadrants of the peripapillary sclera. | T=7 years of the 3C cohort | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Age-related ocular pathologies, Ophthalmology
IL-7 Receptor Polymorphisms and Immune Recovery With HAART

Study Overview
=================
Brief Summary
-----------------
The aim is to investigate the hypothesis that IL7-receptor polymorphisms contribute to the differential immune recovery of CD4 + T cells following HAART

Detailed Description
-----------------
AIM: To examine the association between the four haplotypes of IL-7Rα gene and a cohort of HIV infected patients who have commenced HAART with varying CD4+ T lymphocyte responses. METHODS: IL-7Rα gene SNPs and haplotypes will be measured by constructing DNA pools, and PCR amplification and DNA sequencing. IL-7Rα expression will be examined using constitutive expression of IL-7Rα, IL-7Rα gene expression, and inducible expression of IL7Rα.

Official Title
-----------------
The Relationship of Single Nucleotide Polymorphisms in the Interleukin-7 Receptor-α Gene to CD4+ Immune Recovery in HIV Infected Patients Who Begin Antiretroviral Treatment With HAART

Conditions
-----------------
HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women at least 18 years of age First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of ≤ 500 copies/mL on bDNA testing (versions 2 and 3) and <400 copies/ml measured by RT-PCR assay by 6 months treatment. CD4 cell count <500 at commencement of HAART Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART. Exclusion Criteria: Exclude patients treated for HIV seroconversion illness Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment Experienced, HIV
Korean Coronary Bifurcation Stenting (COBIS) Registry III

Study Overview
=================
Brief Summary
-----------------
The COBIS III registry is a multi-center, real-world registry of 2nd generation drug-eluting stenting in coronary bifurcation lesions in South Korea. From 21 major coronary intervention centers in Korea, a total of 3,000 patients (anticipated) will be enrolled in this database between January 2010 and December 2014. The aim of the study was to investigate long-term clinical results and predictors of adverse outcomes after percutaneous coronary intervention with 2nd generation drug-eluting stents for coronary bifurcation lesions in South Korea.

Official Title
-----------------
Multicenter, Retrospective Korean Coronary Bifurcation Stenting (COBIS) Registry III

Conditions
-----------------
Coronary Bifurcation Lesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=19 years Any type of de novo bifurcation lesion in major epicardial artery: unprotected left main coronary bifurcation lesion, LAD - diagonal, LCX-OM, distal RCA bifurcation. (Excluding RCA-RV branch bifurcation, branch bifurcation) Side branch or LCX reference diameter >= 2.3 mm and at least stentable with 2.5 mm stent Treated with drug-eluting stent during the period of 2010. 1   2014. 12 Exclusion Criteria: Protected left main disease previous CABG for LAD or LCX territory Cardiogenic Shock History of CPR in the same hospitalization Patients with severe left ventricular systolic dysfunction (ejection fraction < 30%)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Coronary Bifurcation Lesion<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target lesion failure | composite of cardiac death, myocardial infarction, or target lesion revascularization | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac death | All deaths were considered cardiac cause unless obvious non-cardiac causes could be identified | 5 years | 
| Myocardial infarction | an elevation of creatine kinase-myocardial band or troponin level greater than the upper limit of normal with concomitant ischemic symptoms or electrocardiography findings indicative of ischemia | 5 years | 
| Target lesion revascularization | repeat PCI of the lesion within 5 mm of the inserted stent | 3 years | 
| Stent thrombosis | the Academic Research Consortium as definite, probable, or possible | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Bifurcation Lesion, 2nd generation drug-eluting stent
The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
To explore the protective effect of prostaglandin sodium on coronary microcirculation function and ventricular remodeling after reperfusion treatment of acute ST-segment elevation myocardial infarction.

Official Title
-----------------
The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

Conditions
-----------------
STEMI

Intervention / Treatment
-----------------
* Drug: beprostaglandin sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Meet the diagnostic criteria for acute ST-segment elevation myocardial infarction: ①The onset of ischemic chest pain lasts for more than 30 minutes and cannot be relieved by taking nitroglycerin; ②The ECG has two or more ST-segment elevations in adjacent leads , Limb leads ≥ 1mm, pectoral leads ≥ 2mm; or newly-appearing left bundle branch block; ③The increase in serum markers of myocardial necrosis is at least twice the normal value; (2) Coronary angiography confirmed acute myocardial infarction; (3) Direct PCI treatment within 12 hours of onset; (4) Complete clinical and radiographic data. Exclusion Criteria: (1) Those who do not cooperate in the inspection, have poor compliance, and cannot guarantee the completion of the test; (2) Persons with consciousness impairment, obvious intellectual impairment and mental abnormality; (3) With metal foreign bodies, such as metal prostheses, intraocular metal foreign bodies, intracranial aneurysm clamps, etc.; (4) Those who suffer from closure phobia; (5) Those who have had a history of myocardial infarction, PCI treatment, or coronary artery bypass graft; (6) Factors affecting the changes in the ST segment of the electrocardiogram: complete left bundle branch block, pre-excitation syndrome, pacemaker electrocardiogram

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: beprostaglandin sodium<br> | Drug: beprostaglandin sodium<br>* beprostaglandin sodium<br>|
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ultrasound and CMR to assess the characteristics of myocardial infarction | Q-LAB Scale Scale calculation score | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Beprostaglandin sodium
Do Common Physical Tests Predict Injury or Performance

Study Overview
=================
Brief Summary
-----------------
Field tests are convenient, simple tests that serve as estimates of components of athletic performance like power speed, and agility. It is thought clinically, that those who do best at these tests will perform the best in their sport and/or be the least likely to get injured. The converse is also thought to be true. The objective of this study is to administer field tests to athletes at the beginning of each season and then follow athletes over several years, tracking their injuries and their performance statistics. In this way, the investigators can determine if the clinical supposition is true and that the results of field tests are associated with injury or performance

Detailed Description
-----------------
11 physical performance tests were examined to determine their ability to predict injury

Official Title
-----------------
Field Tests and Their Correlation With Injury and Performance

Conditions
-----------------
Lower Extremity Musculoskeletal Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age18-23 member of the university's varsity teams Exclusion Criteria: injured or recently injured prior to testing diagnosed current neurological issue recent (within 6 weeks) surgery where strenuous physical testing would be contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| athletes with lower extremity injury<br>athletes who were injured during one season of play | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| injury |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| performance |  | 1 season |
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals

Study Overview
=================
Brief Summary
-----------------
The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.

Detailed Description
-----------------
The trial was designed as a real-world observational study to recruit those patients with pathologically diagnosed early-phase non-small cell lung cancer (NSCLC) who were enrolled in the clinical form 2009 to 2017 and explore recurrence/metastases of the NSCLC patients as measured by patient survivals and the impact factors of patient survivals. The study data on patient demographic characteristics, tumor biological characteristics, and clinicla treatments were collected via a retrospectively review method for evaluation of patient survivals and the relevance of clinical characteristics of the patients and patient survivals.

Official Title
-----------------
A Real-world Study to Explore Recurrence/Metastases of the Early-stage (I-IIIA) NSCLC Patients and the Impact Factors of Patient Survivals

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Surgeries


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients who meet all the following inclusion criteria will be included in the study: The patients who were operated with radical operations of the lung cancer; The patients with clinical I-IIIA staging tumors; The pathologically diagnosed NSCLC patients; Exclusion Criteria: - Not be specified;
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Surgeries|Surgical operations plus systematic lymphadenectomies|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival rates within the configured observation periods | Disease-free survival rates within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods; | 2009-2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival rates at the configured locations and observation periods | Disease-free survival rates at the metastasized lymph nodes, bone, and brain within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods; | 2009-2017 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
early-stage NSCLC, real-world evidences, patient survivals
High Sensitive CRP in Prediabetics and Diabetes

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to study the level of high-sensitivity CRP in sera of pre-diabetic and newly diagnosed patients with type 2 diabetes mellitus and its correlation with HOMA IR and HbA1c

Detailed Description
-----------------
This study will include (180) subjects, 60 pre-diabetic patients, 60 patients with newly diagnosed type 2 diabetes ( within one month of diagnosis) and 60 normal healthy non diabetic individuals as a control group. The study individuals will be recruited from the Diabetes and Internal Medicine Clinics of Fayoum University Hospital

Official Title
-----------------
High Sensitive CRP Level in Prediabetics and Newly Diagnosed Type 2 Diabetic Patients

Conditions
-----------------
Assess Level of High Sensitive CRP in Diabetics and Prediabetics

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pre-diabetic patients: A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%. Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/dl Hb A1C > 6.5% Exclusion Criteria: Pregnant or lactating females. Patients who have recent infection. Patients with acute inflammatory diseases as autoimmune diseases. Patients with malignancy or on chemotherapy. Patients with acute or chronic liver or renal diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prediabetics<br>Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%. | |
| Newly diagnosed type 2 diabetes<br>Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5% | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| statistical significant elevation of high sensitive CRP in diabetics and prediabetes |  | 2 years |
Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify that the incidence rate of urinary tract infections after a routine outpatient cystoscopy is the same for non-sterile (clean) and sterile procedural techniques.

Official Title
-----------------
Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy

Conditions
-----------------
Urinary Tract Infections

Intervention / Treatment
-----------------
* Procedure: clean patient preparation for cystoscopy
* Procedure: sterile patient preparation for cystoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Patients undergoing routine outpatient flexible cystoscopy Exclusion Criteria: Patients who have had a urinary tract infection within 3 months prior to flexible cystoscopy Patients with an indwelling catheter

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: clean patient preparation for cystoscopy|nan|
|Procedure: sterile patient preparation for cystoscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To verify that the incidence rate of urinary tract infections after a routine outpatient cystoscopy is the same for non-sterile (clean) and sterile procedural techniques |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cystoscopy